Explaining, not just predicting, drives interest in personal genomics

DSpace/Manakin Repository

Explaining, not just predicting, drives interest in personal genomics

Citable link to this page

 

 
Title: Explaining, not just predicting, drives interest in personal genomics
Author: Meisel, Susanne F.; Carere, Deanna Alexis; Wardle, Jane; Kalia, Sarah S.; Moreno, Tanya A.; Mountain, Joanna L.; Roberts, J. Scott; Green, Robert C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Meisel, Susanne F., Deanna Alexis Carere, Jane Wardle, Sarah S. Kalia, Tanya A. Moreno, Joanna L. Mountain, J. Scott Roberts, and Robert C. Green. 2015. “Explaining, not just predicting, drives interest in personal genomics.” Genome Medicine 7 (1): 74. doi:10.1186/s13073-015-0188-5. http://dx.doi.org/10.1186/s13073-015-0188-5.
Full Text & Related Files:
Abstract: Background: There is a widespread assumption that risk prediction is the major driver of customer interest in personal genomic testing (PGT). However, some customers may also be motivated by finding out whether their existing diseases have a genetic etiology. We evaluated the impact of an existing medical diagnosis on customer interest in condition-specific results from PGT. Methods: Using a prospective online survey of PGT customers, we measured customer interest prior to receiving PGT results for 11 health conditions, and examined the association between interest and personal medical history of these conditions using logistic regression. Results: We analyzed data from 1,538 PGT customers, mean age 48.7 years, 61 % women, 90 % White, and 47 % college educated. The proportion of customers who were ‘very interested’ in condition-specific PGT varied considerably, from 28 % for ulcerative colitis to 68% for heart disease. After adjusting for demographic and personal characteristics including family history, having a diagnosis of the condition itself was significantly associated with interest in genetic testing for risk of that condition, with odds ratios ranging from 2.07 (95 % CI 1.28-3.37) for diabetes to 19.99 (95 % CI 4.57-87.35) for multiple sclerosis. Conclusions: PGT customers are particularly interested in genetic markers for their existing medical conditions, suggesting that the value of genetic testing is not only predictive, but also explanatory. Electronic supplementary material The online version of this article (doi:10.1186/s13073-015-0188-5) contains supplementary material, which is available to authorized users.
Published Version: doi:10.1186/s13073-015-0188-5
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533947/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462033
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters